Journal articleExpert Rev Pharmacoecon Outcomes Res2020
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
- Journal
- Expert Rev Pharmacoecon Outcomes Res
- Published
- 10 October 2019
- Citations
- 5
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try